董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Anne E. Borgman | -- | Director | -- | 未披露 | 未持股 | 2026-03-24 |
| John A. Hohneker | -- | Director | -- | 未披露 | 未持股 | 2026-03-24 |
| Martyn D. Greenacre | 男 | Chairman of the Board | 84 | 8.60万美元 | 未持股 | 2026-03-24 |
| Kenneth I. Kaitin | 男 | Director | 72 | 7.87万美元 | 未持股 | 2026-03-24 |
| Marc Rubin | 男 | Director | 70 | 7.72万美元 | 未持股 | 2026-03-24 |
| James E. Dentzer | 男 | Chief Executive Officer and President,Director | 60 | 未披露 | 未持股 | 2026-03-24 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Diantha Duvall | 女 | Chief Financial Officer | 54 | 未披露 | 未持股 | 2026-03-24 |
| Jonathan Zung | 男 | Chief Development Officer | 61 | 未披露 | 未持股 | 2026-03-24 |
| Ahmed Hamdy | 男 | Chief Medical Officer | 61 | 未披露 | 未持股 | 2026-03-24 |
| James E. Dentzer | 男 | Chief Executive Officer and President,Director | 60 | 未披露 | 未持股 | 2026-03-24 |
董事简历
中英对照 | 中文 | 英文- Anne E. Borgman
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- John A. Hohneker
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Martyn D. Greenacre
-
Martyn D. Greenacre，2000年2月起，他在Curis, Inc.董事会任职；1993年6月至2000年7月，他是Creative BioMolecules（生命科学公司前身）董事；2001年9月起，他是Life Mist L.L.C（消防领域的私营公司）总裁；1997年6月至2001年6月，他是Delsys Pharmaceutical Corporation（药物制剂公司）首席行政官；1993年至1997年，他是Zynaxis（生物制药公司）总裁和首席行政官；在加入Zynaxis之前，1973年至1992年，他在SmithKline Beecham担任多个高级管理职务。他还曾在Neostem、 Acusphere和Formula Pharmaceuticals担任董事。在那之前，他在Cephalon和 Orchestra Therapeutics担任董事，也是BMP Sunstone Corporation董事和主席。他获有哈佛大学商学院工商管理硕士学位以及哈佛大学学士学位。
Martyn D. Greenacre has served on Curis, Inc.'s board since February 2000 and was a director of Creative BioMolecules, Inc., a predecessor life science company, from June 1993 to July 2000. Mr. Greenacre has served as Chairman of Life Mist L.L.C., a privately-held company in the field of fire suppression, since September 2001. From June 1997 to June 2001 Mr. Greenacre was Chief Executive Officer of Delsys Pharmaceutical Corporation, a drug formulation company. From 1993 to 1997 Mr. Greenacre was President and Chief Executive Officer of Zynaxis, Inc., a biopharmaceutical company. Prior to Zynaxis, Inc., Mr. Greenacre served in various senior management positions at SmithKline Beecham, a pharmaceuticals company, from 1973 through 1992. Mr. Greenacre also serves as a director of Formula Pharmaceuticals. Previously, Mr. Greenacre served as a director of Acusphere, Inc., Cephalon, Inc., Neostem, Inc. n/k/a Caladrius and Orchestra Therapeutics, Inc., and as a director and Chairman of BMP Sunstone Corporation. Mr. Greenacre received an M.B.A. from Harvard Business School and a B.A. from Harvard College. - Martyn D. Greenacre，2000年2月起，他在Curis, Inc.董事会任职；1993年6月至2000年7月，他是Creative BioMolecules（生命科学公司前身）董事；2001年9月起，他是Life Mist L.L.C（消防领域的私营公司）总裁；1997年6月至2001年6月，他是Delsys Pharmaceutical Corporation（药物制剂公司）首席行政官；1993年至1997年，他是Zynaxis（生物制药公司）总裁和首席行政官；在加入Zynaxis之前，1973年至1992年，他在SmithKline Beecham担任多个高级管理职务。他还曾在Neostem、 Acusphere和Formula Pharmaceuticals担任董事。在那之前，他在Cephalon和 Orchestra Therapeutics担任董事，也是BMP Sunstone Corporation董事和主席。他获有哈佛大学商学院工商管理硕士学位以及哈佛大学学士学位。
- Martyn D. Greenacre has served on Curis, Inc.'s board since February 2000 and was a director of Creative BioMolecules, Inc., a predecessor life science company, from June 1993 to July 2000. Mr. Greenacre has served as Chairman of Life Mist L.L.C., a privately-held company in the field of fire suppression, since September 2001. From June 1997 to June 2001 Mr. Greenacre was Chief Executive Officer of Delsys Pharmaceutical Corporation, a drug formulation company. From 1993 to 1997 Mr. Greenacre was President and Chief Executive Officer of Zynaxis, Inc., a biopharmaceutical company. Prior to Zynaxis, Inc., Mr. Greenacre served in various senior management positions at SmithKline Beecham, a pharmaceuticals company, from 1973 through 1992. Mr. Greenacre also serves as a director of Formula Pharmaceuticals. Previously, Mr. Greenacre served as a director of Acusphere, Inc., Cephalon, Inc., Neostem, Inc. n/k/a Caladrius and Orchestra Therapeutics, Inc., and as a director and Chairman of BMP Sunstone Corporation. Mr. Greenacre received an M.B.A. from Harvard Business School and a B.A. from Harvard College.
- Kenneth I. Kaitin
-
Kenneth I. Kaitin，他获有医学博士学位。2003年11月起，他在Curis, Inc.董事会任职；1998年起，他成为药物开发研究Tufts Center（为帮助药物开发人员、监管机构和政策制定者提高药物质量和开发过程效率提供战略信息的学术药物政策研究集团）董事；2010年起，他在Tufts University School of Medicine受到任命，第一次是被任命为研究教授，第二次被任命为医药教授和药理学与实验治疗教授。1999年起，他担任巴塞尔大学欧洲医药中心教员；2006年起，他在达特茅斯大学塔克商学院担任客座讲师；2003年至2009年，他是Tufts University School of Medicine的医学副教授。他就医药发展问题写了大量的文章，并在美国的国会听证会上，为药物创新与食品药物管理局改革提供公共证词。作为一个国际认证的药物研发专家，他经常被引用在研究型制药产业和新的创新模式的商业和贸易出版社的研究和发展趋势中。他是Drug Information Journal的前总编辑；1997年至1998年，他是Drug Information Association总裁。目前，他是Expert Review of Clinical Pharmacology的总编辑，并在一些同行评审期刊的编辑委员会任职。他是美国国防部就生物恐怖对策问题的专家顾问。他还是io-Tree Systems（私营情报公司）、Centerphase Solutions（私营信息技术公司）以及New England Healthcare Institute（非盈利机构）董事。他曾在Phase Forward Inc. and Erevnos Corporation担任董事。他获有罗彻斯特大学医药硕士学位和医学博士学位以及康奈尔大学学士学位。
Kenneth I. Kaitin has served on Curis, Inc.'s board since November 2003. Since July 1998 Dr. Kaitin has been the Director of the Tufts Center for the Study of Drug Development, an academic drug policy research group providing strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of the drug development process. Since August 2014 Dr. Kaitin has held a primary appointment as Professor of Public Health and Community Medicine at the Tufts University School of Medicine, as well as secondary appointments as Professor of Medicine and Professor of Integrative Physiology and Pathobiology at Tufts University School of Medicine. In December 2014 Dr. Kaitin received the appointment of Advisory Professor at Shanghai Medical College of Fudan University. Since September 1999 he has served on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel, and since April 2006 he has been a Visiting Executive at the Tuck School of Business at Dartmouth College. At the Tufts University School of Medicine, Dr. Kaitin was a Research Associate Professor of Medicine from October 2003 to May 2008 and a Research Professor from May 2008 to August 2014. Dr. Kaitin has written extensively on a broad range of drug development issues and has provided public testimony before the U.S. Congress in hearings on pharmaceutical innovation and FDA reform. An internationally recognized expert on the science of drug development, Dr. Kaitin is regularly quoted in the business and trade press on R&D trends in the research-based drug industry and new models of innovation. In 2011 Dr. Kaitin received the Dr. Louis M. Sherwood Award granted by the Academy of Pharmaceutical Physicians and Investigators. Dr. Kaitin is a former Editor-in-Chief of the Drug Information Journal, and from 1997 to 1998 he was President of the Drug Information Association. He is currently Editor-in-Chief of Expert Review of Clinical Pharmacology, and he serves on the editorial boards of a number of peer-review journals. Dr. Kaitin serves as an expert consultant to the U.S. Department of Defense on Bioterror Countermeasure issues. Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University. - Kenneth I. Kaitin，他获有医学博士学位。2003年11月起，他在Curis, Inc.董事会任职；1998年起，他成为药物开发研究Tufts Center（为帮助药物开发人员、监管机构和政策制定者提高药物质量和开发过程效率提供战略信息的学术药物政策研究集团）董事；2010年起，他在Tufts University School of Medicine受到任命，第一次是被任命为研究教授，第二次被任命为医药教授和药理学与实验治疗教授。1999年起，他担任巴塞尔大学欧洲医药中心教员；2006年起，他在达特茅斯大学塔克商学院担任客座讲师；2003年至2009年，他是Tufts University School of Medicine的医学副教授。他就医药发展问题写了大量的文章，并在美国的国会听证会上，为药物创新与食品药物管理局改革提供公共证词。作为一个国际认证的药物研发专家，他经常被引用在研究型制药产业和新的创新模式的商业和贸易出版社的研究和发展趋势中。他是Drug Information Journal的前总编辑；1997年至1998年，他是Drug Information Association总裁。目前，他是Expert Review of Clinical Pharmacology的总编辑，并在一些同行评审期刊的编辑委员会任职。他是美国国防部就生物恐怖对策问题的专家顾问。他还是io-Tree Systems（私营情报公司）、Centerphase Solutions（私营信息技术公司）以及New England Healthcare Institute（非盈利机构）董事。他曾在Phase Forward Inc. and Erevnos Corporation担任董事。他获有罗彻斯特大学医药硕士学位和医学博士学位以及康奈尔大学学士学位。
- Kenneth I. Kaitin has served on Curis, Inc.'s board since November 2003. Since July 1998 Dr. Kaitin has been the Director of the Tufts Center for the Study of Drug Development, an academic drug policy research group providing strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of the drug development process. Since August 2014 Dr. Kaitin has held a primary appointment as Professor of Public Health and Community Medicine at the Tufts University School of Medicine, as well as secondary appointments as Professor of Medicine and Professor of Integrative Physiology and Pathobiology at Tufts University School of Medicine. In December 2014 Dr. Kaitin received the appointment of Advisory Professor at Shanghai Medical College of Fudan University. Since September 1999 he has served on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel, and since April 2006 he has been a Visiting Executive at the Tuck School of Business at Dartmouth College. At the Tufts University School of Medicine, Dr. Kaitin was a Research Associate Professor of Medicine from October 2003 to May 2008 and a Research Professor from May 2008 to August 2014. Dr. Kaitin has written extensively on a broad range of drug development issues and has provided public testimony before the U.S. Congress in hearings on pharmaceutical innovation and FDA reform. An internationally recognized expert on the science of drug development, Dr. Kaitin is regularly quoted in the business and trade press on R&D trends in the research-based drug industry and new models of innovation. In 2011 Dr. Kaitin received the Dr. Louis M. Sherwood Award granted by the Academy of Pharmaceutical Physicians and Investigators. Dr. Kaitin is a former Editor-in-Chief of the Drug Information Journal, and from 1997 to 1998 he was President of the Drug Information Association. He is currently Editor-in-Chief of Expert Review of Clinical Pharmacology, and he serves on the editorial boards of a number of peer-review journals. Dr. Kaitin serves as an expert consultant to the U.S. Department of Defense on Bioterror Countermeasure issues. Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University.
- Marc Rubin
-
Marc Rubin，博士，自2011年10月起出任董事。现任Titan Pharmaceuticals, Inc.（TTNP： OTC BB）的董事局执行主席。从2007年10月至2009年1月担任其总裁兼首席执行官。曾担任Bayer Schering Pharma的全球研发部负责人，以及Bayer Healthcare执行委员会和Bayer Schering Pharm的管理委员会的成员，直到2007年2月。2006年6月Bayer Pharmaceuticals和Schering AG合并之前，自2003年10月加入Schering AG 起担任执行委员会的成员，以及Schering Berlin Inc.的董事长和Berlex Pharmaceuticals（Schering AG的一个部门）的总裁。从1990年到2003年8月，他受聘于GlaxoSmithKline，负责监督在美国、欧洲、亚洲和拉丁美洲的全球临床和商业发展项目。从2001年到2003年任职于GlaxoSmithKline，他是全球临床药理学与探索医学的高级副总裁。毕业于美国康奈尔大学医学院，获得医学博士学位，并且是内科与肿瘤内科和传染病亚专科委员会认证的一员。现任Curis Inc.（纳斯达克股票代码：CRIS）的董事会成员。曾担任Medarex, Inc.（现Bristol-Myers Squibb Company的附属公司）的董事。
Marc Rubin a director since October 2011 and Chairman of the Board from January 2016 through May 2018, is Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Inc. (TTNP: OTC BB) and served as its President and Chief Executive Officer from October 2007 to January 2009. Until February 2007, Dr. Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as ll as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG since joining the company in October 2003, as ll as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until Augt 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions of responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003 at GlaxoSmithKline, he was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine. Dr. Rubin holds an M.D. from Cornell University Medical College and is board certified in internal medicine with subspecialties in medical oncology and infectio diseases. Dr. Rubin is a member of the Board of Directors of Curis Inc. (Nasdaq: CRIS) and formerly served on the Board of Directors of Medarex, Inc., now a subsidiary of Bristol Myers Squibb Company. - Marc Rubin，博士，自2011年10月起出任董事。现任Titan Pharmaceuticals, Inc.（TTNP： OTC BB）的董事局执行主席。从2007年10月至2009年1月担任其总裁兼首席执行官。曾担任Bayer Schering Pharma的全球研发部负责人，以及Bayer Healthcare执行委员会和Bayer Schering Pharm的管理委员会的成员，直到2007年2月。2006年6月Bayer Pharmaceuticals和Schering AG合并之前，自2003年10月加入Schering AG 起担任执行委员会的成员，以及Schering Berlin Inc.的董事长和Berlex Pharmaceuticals（Schering AG的一个部门）的总裁。从1990年到2003年8月，他受聘于GlaxoSmithKline，负责监督在美国、欧洲、亚洲和拉丁美洲的全球临床和商业发展项目。从2001年到2003年任职于GlaxoSmithKline，他是全球临床药理学与探索医学的高级副总裁。毕业于美国康奈尔大学医学院，获得医学博士学位，并且是内科与肿瘤内科和传染病亚专科委员会认证的一员。现任Curis Inc.（纳斯达克股票代码：CRIS）的董事会成员。曾担任Medarex, Inc.（现Bristol-Myers Squibb Company的附属公司）的董事。
- Marc Rubin a director since October 2011 and Chairman of the Board from January 2016 through May 2018, is Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Inc. (TTNP: OTC BB) and served as its President and Chief Executive Officer from October 2007 to January 2009. Until February 2007, Dr. Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as ll as a member of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Prior to the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG since joining the company in October 2003, as ll as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until Augt 2003, Dr. Rubin was employed by GlaxoSmithKline where he held positions of responsibility in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003 at GlaxoSmithKline, he was Senior Vice President of Global Clinical Pharmacology & Discovery Medicine. Dr. Rubin holds an M.D. from Cornell University Medical College and is board certified in internal medicine with subspecialties in medical oncology and infectio diseases. Dr. Rubin is a member of the Board of Directors of Curis Inc. (Nasdaq: CRIS) and formerly served on the Board of Directors of Medarex, Inc., now a subsidiary of Bristol Myers Squibb Company.
- James E. Dentzer
-
James E. Dentzer，他于2013年12月担任财务总监。自2010年3月至2013年12月，他在Valeritas公司担任财务总监，带领其金融团队在C轮筹集了价值1.5亿美元的股票以及价值1亿美元的债务，得到了食品药物管理局（U.S. Food and Drug Administration）的支持和引导，并更大规模的制造并销售V-Go 胰岛素传输设备。在进入Valeritas公司前，即自2006年10月至2009年10月，他在Amicus Therapeutics公司（NASDAQ股票代码FOLD）担任财务总监，引领公司进行了D系列的优先股融资以及首次公开募股。他在Biogen Idec公司担任了6年财务总监，并在E.I. du Pont de Nemours 公司及其位于美国和亚洲的分公司里担任了6年的各种高级财务管理职位。他在波士顿学院（Boston College）获得哲学学士学位，并在芝加哥大学（University of Chicago）获得工商管理硕士学位。
James E. Dentzer was appointed to Imunon, Inc. Board of Directors in September 2022. He has been President and Chief Executive Officer and a member of the Board of Directors of Curis, Inc. (Nasdaq: CRIS) since September 2018. From March 2018 to September 2018, Mr. Dentzer served as Curis' Chief Operating Officer and Chief Financial Officer. From March 2016 to March 2018, Mr. Dentzer served as Curis' Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer has also held the positions of secretary and treasurer from March 2016 to March 2019. Prior to joining Curis, Mr. Dentzer served as Chief Financial Officer of Dicerna Pharmaceuticals, Inc., a formerly publicly traded biotechnology company, from December 2013 to December 2015. Prior to that, he was the Chief Financial Officer of Valeritas, Inc., a formerly publicly traded medical technology company, from March 2010 to December 2013. Prior to joining Valeritas, Inc., he was the Chief Financial Officer of Amicus Therapeutics, Inc. (Nasdaq: FOLD), a biotechnology company, from October 2006 to October 2009. In prior positions, he spent six years as Corporate Controller of Biogen Inc. (Nasdaq: BIIB), a biotechnology company, and six years in various senior financial roles at E.I. du Pont de Nemours and Company, a chemical, petroleum, and biotechnology company, in the U.S. and Asia. Mr. Dentzer holds a B.A. degree in Philosophy from Boston College and an M.B.A. from the University of Chicago. - James E. Dentzer，他于2013年12月担任财务总监。自2010年3月至2013年12月，他在Valeritas公司担任财务总监，带领其金融团队在C轮筹集了价值1.5亿美元的股票以及价值1亿美元的债务，得到了食品药物管理局（U.S. Food and Drug Administration）的支持和引导，并更大规模的制造并销售V-Go 胰岛素传输设备。在进入Valeritas公司前，即自2006年10月至2009年10月，他在Amicus Therapeutics公司（NASDAQ股票代码FOLD）担任财务总监，引领公司进行了D系列的优先股融资以及首次公开募股。他在Biogen Idec公司担任了6年财务总监，并在E.I. du Pont de Nemours 公司及其位于美国和亚洲的分公司里担任了6年的各种高级财务管理职位。他在波士顿学院（Boston College）获得哲学学士学位，并在芝加哥大学（University of Chicago）获得工商管理硕士学位。
- James E. Dentzer was appointed to Imunon, Inc. Board of Directors in September 2022. He has been President and Chief Executive Officer and a member of the Board of Directors of Curis, Inc. (Nasdaq: CRIS) since September 2018. From March 2018 to September 2018, Mr. Dentzer served as Curis' Chief Operating Officer and Chief Financial Officer. From March 2016 to March 2018, Mr. Dentzer served as Curis' Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer has also held the positions of secretary and treasurer from March 2016 to March 2019. Prior to joining Curis, Mr. Dentzer served as Chief Financial Officer of Dicerna Pharmaceuticals, Inc., a formerly publicly traded biotechnology company, from December 2013 to December 2015. Prior to that, he was the Chief Financial Officer of Valeritas, Inc., a formerly publicly traded medical technology company, from March 2010 to December 2013. Prior to joining Valeritas, Inc., he was the Chief Financial Officer of Amicus Therapeutics, Inc. (Nasdaq: FOLD), a biotechnology company, from October 2006 to October 2009. In prior positions, he spent six years as Corporate Controller of Biogen Inc. (Nasdaq: BIIB), a biotechnology company, and six years in various senior financial roles at E.I. du Pont de Nemours and Company, a chemical, petroleum, and biotechnology company, in the U.S. and Asia. Mr. Dentzer holds a B.A. degree in Philosophy from Boston College and an M.B.A. from the University of Chicago.
高管简历
中英对照 | 中文 | 英文- Diantha Duvall
Diantha Duvall，自2022年8月起担任Curis, Inc.首席财务官。在此之前，Duvall女士于2019年3月至2022年6月担任Genocea Biosciences, Inc.的首席财务官，该公司是一家专注于开发新抗原癌症免疫疗法的生物技术公司。2017年2月至2019年1月，杜瓦尔女士在Bioverativ公司担任副总裁、财务和首席会计官，该公司是一家专注于治疗血友病和其他罕见血液疾病的生物制药公司。在加入Bioverativ公司之前，杜瓦尔女士分别于2016年和2015年担任渤健公司的全球商务总监和美国商务总监。在加入Biogen Inc.之前，杜瓦尔女士曾于2009年至2015年在制药公司默克公司担任多个职位，并于1996年至2009年在会计师事务所普华永道担任多个职位。杜瓦尔拥有科尔比学院的经济学和公共政策学士学位，以及东北大学的会计学硕士和MBA学位。
Diantha Duvall has served as Chief Financial Officer since Augt 2022. From March 2019 to June 2022, Ms. Duvall served as Chief Financial Officer of Genocea Biosciences, Inc., a biotechnology company foced on the development of cancer immunotherapies. From February 2017 to January 2019, Ms. Duvall served as Vice President, Finance and Chief Accounting Officer at Bioverativ, Inc., a biopharmaceutical company foced on therapies for hemophilia and other rare blood disorders. Prior to joining Bioverativ, Inc., Ms. Duvall was Global Commercial Controller and U.S. Commercial Controller at Biogen in 2016 and 2015, respectively. Prior to Biogen, Ms. Duvall held positions of increasing responsibility at Merck and Co., Inc., a pharmaceutical company and PricewaterhoeCoopers LLP, a registered accounting firm. Ms. Duvall holds a B.A. in economics and public policy from Colby College and an M.S. in accounting and M.B.A. from Northeastern University.- Diantha Duvall，自2022年8月起担任Curis, Inc.首席财务官。在此之前，Duvall女士于2019年3月至2022年6月担任Genocea Biosciences, Inc.的首席财务官，该公司是一家专注于开发新抗原癌症免疫疗法的生物技术公司。2017年2月至2019年1月，杜瓦尔女士在Bioverativ公司担任副总裁、财务和首席会计官，该公司是一家专注于治疗血友病和其他罕见血液疾病的生物制药公司。在加入Bioverativ公司之前，杜瓦尔女士分别于2016年和2015年担任渤健公司的全球商务总监和美国商务总监。在加入Biogen Inc.之前，杜瓦尔女士曾于2009年至2015年在制药公司默克公司担任多个职位，并于1996年至2009年在会计师事务所普华永道担任多个职位。杜瓦尔拥有科尔比学院的经济学和公共政策学士学位，以及东北大学的会计学硕士和MBA学位。
- Diantha Duvall has served as Chief Financial Officer since Augt 2022. From March 2019 to June 2022, Ms. Duvall served as Chief Financial Officer of Genocea Biosciences, Inc., a biotechnology company foced on the development of cancer immunotherapies. From February 2017 to January 2019, Ms. Duvall served as Vice President, Finance and Chief Accounting Officer at Bioverativ, Inc., a biopharmaceutical company foced on therapies for hemophilia and other rare blood disorders. Prior to joining Bioverativ, Inc., Ms. Duvall was Global Commercial Controller and U.S. Commercial Controller at Biogen in 2016 and 2015, respectively. Prior to Biogen, Ms. Duvall held positions of increasing responsibility at Merck and Co., Inc., a pharmaceutical company and PricewaterhoeCoopers LLP, a registered accounting firm. Ms. Duvall holds a B.A. in economics and public policy from Colby College and an M.S. in accounting and M.B.A. from Northeastern University.
- Jonathan Zung
Jonathan Zung自2023年5月起担任首席开发官。2021年1月至2023年3月，Zung博士担任临床阶段生物技术公司Evelo Biosciences, Inc.的首席开发官。Zung博士于2020年5月至2020年12月期间担任临床服务提供商WCG Clinical的赞助商和CRO项目总裁，并于2018年6月至2020年5月期间担任现场事业部总裁。2016年4月至2018年4月，Zung博士在合同研究机构Covance，Inc.担任临床开发和商业化服务组织集团总裁。在加入Covance，Inc.之前，曾博士曾在UCB Biosciences、百时美施贵宝和辉瑞担任领导职务。Zung博士拥有佛罗里达理工学院的化学学士学位和埃默里大学的分析化学博士学位。
Jonathan Zung has served as Chief Development Officer since May 2023. From January 2021 to March 2023, Dr. Zung served as Chief Development Officer of Evelo Biosciences, Inc., a clinical stage biotechnology company. From May 2020 to December 2020, Dr. Zung served as President of Sponsor and CRO programs of WCG Clinical, a clinical services provider, and from June 2018 to May 2020, he served as President of Site Division. From April 2016 to April 2018, Dr. Zung was Group President of Clinical Development and Commercialization Services Organization at Covance, Inc., a contract research organization. Prior to Covance, Inc., Dr. Zung held leadership roles at UCB Biosciences, Bristol Myers Squibb, and Pfizer. Dr. Zung holds a B.S. in chemistry from Florida Institute of Technology and a Ph.D. in analytical chemistry from Emory University.- Jonathan Zung自2023年5月起担任首席开发官。2021年1月至2023年3月，Zung博士担任临床阶段生物技术公司Evelo Biosciences, Inc.的首席开发官。Zung博士于2020年5月至2020年12月期间担任临床服务提供商WCG Clinical的赞助商和CRO项目总裁，并于2018年6月至2020年5月期间担任现场事业部总裁。2016年4月至2018年4月，Zung博士在合同研究机构Covance，Inc.担任临床开发和商业化服务组织集团总裁。在加入Covance，Inc.之前，曾博士曾在UCB Biosciences、百时美施贵宝和辉瑞担任领导职务。Zung博士拥有佛罗里达理工学院的化学学士学位和埃默里大学的分析化学博士学位。
- Jonathan Zung has served as Chief Development Officer since May 2023. From January 2021 to March 2023, Dr. Zung served as Chief Development Officer of Evelo Biosciences, Inc., a clinical stage biotechnology company. From May 2020 to December 2020, Dr. Zung served as President of Sponsor and CRO programs of WCG Clinical, a clinical services provider, and from June 2018 to May 2020, he served as President of Site Division. From April 2016 to April 2018, Dr. Zung was Group President of Clinical Development and Commercialization Services Organization at Covance, Inc., a contract research organization. Prior to Covance, Inc., Dr. Zung held leadership roles at UCB Biosciences, Bristol Myers Squibb, and Pfizer. Dr. Zung holds a B.S. in chemistry from Florida Institute of Technology and a Ph.D. in analytical chemistry from Emory University.
- Ahmed Hamdy
Ahmed Hamdy先生是一名医学博士，自2009年3月开始一直担任首席医疗官。从2008年7月至2009年2月，Hamdy博士曾担任伊兰制药公司（Elan Pharmaceuticals）治疗领域负责人，负责胃肠病和自身免疫性的临床开发。2006年2月至2008年6月， Hamdy博士还担任过PDL生物制药公司（ PDL BioPharma）的全科医学治疗领域负责人。2004年9月至2006年2月， Hamdy博士是在Johnson and Johnson/ALZA担任医疗主任。2000年10月至2004年8月，Hamdy博士是华生制药公司（Watson Pharmaceuticals）的高级首席科学家。 Hamdy博士获得了埃及开罗大学的医学博士学位（M.B.B.Ch）。
Ahmed Hamdy,M.D. has served as Chief Medical Officer since March of 2009. From July 2008 to February 2009 Dr. Hamdy served as Therapeutic Area Head at Elan Pharmaceuticals responsible for gastroenterology and autoimmune clinical development. Dr. Hamdy has also served as the General Medicine Therapeutic Area Head at PDL BioPharma from February 2006 to June 2008. From September 2004 to February 2006 Dr. Hamdy was a medical director at Johnson and Johnson/ALZA. From October 2000 to August 2004 Dr. Hamdy was a Senior Principal Scientist at Watson Pharmaceuticals. Dr. Hamdy received his M.D. (M.B.B.Ch) from Cairo University, Egypt.- Ahmed Hamdy先生是一名医学博士，自2009年3月开始一直担任首席医疗官。从2008年7月至2009年2月，Hamdy博士曾担任伊兰制药公司（Elan Pharmaceuticals）治疗领域负责人，负责胃肠病和自身免疫性的临床开发。2006年2月至2008年6月， Hamdy博士还担任过PDL生物制药公司（ PDL BioPharma）的全科医学治疗领域负责人。2004年9月至2006年2月， Hamdy博士是在Johnson and Johnson/ALZA担任医疗主任。2000年10月至2004年8月，Hamdy博士是华生制药公司（Watson Pharmaceuticals）的高级首席科学家。 Hamdy博士获得了埃及开罗大学的医学博士学位（M.B.B.Ch）。
- Ahmed Hamdy,M.D. has served as Chief Medical Officer since March of 2009. From July 2008 to February 2009 Dr. Hamdy served as Therapeutic Area Head at Elan Pharmaceuticals responsible for gastroenterology and autoimmune clinical development. Dr. Hamdy has also served as the General Medicine Therapeutic Area Head at PDL BioPharma from February 2006 to June 2008. From September 2004 to February 2006 Dr. Hamdy was a medical director at Johnson and Johnson/ALZA. From October 2000 to August 2004 Dr. Hamdy was a Senior Principal Scientist at Watson Pharmaceuticals. Dr. Hamdy received his M.D. (M.B.B.Ch) from Cairo University, Egypt.
- James E. Dentzer
James E. Dentzer，他于2013年12月担任财务总监。自2010年3月至2013年12月，他在Valeritas公司担任财务总监，带领其金融团队在C轮筹集了价值1.5亿美元的股票以及价值1亿美元的债务，得到了食品药物管理局（U.S. Food and Drug Administration）的支持和引导，并更大规模的制造并销售V-Go 胰岛素传输设备。在进入Valeritas公司前，即自2006年10月至2009年10月，他在Amicus Therapeutics公司（NASDAQ股票代码FOLD）担任财务总监，引领公司进行了D系列的优先股融资以及首次公开募股。他在Biogen Idec公司担任了6年财务总监，并在E.I. du Pont de Nemours 公司及其位于美国和亚洲的分公司里担任了6年的各种高级财务管理职位。他在波士顿学院（Boston College）获得哲学学士学位，并在芝加哥大学（University of Chicago）获得工商管理硕士学位。
James E. Dentzer was appointed to Imunon, Inc. Board of Directors in September 2022. He has been President and Chief Executive Officer and a member of the Board of Directors of Curis, Inc. (Nasdaq: CRIS) since September 2018. From March 2018 to September 2018, Mr. Dentzer served as Curis' Chief Operating Officer and Chief Financial Officer. From March 2016 to March 2018, Mr. Dentzer served as Curis' Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer has also held the positions of secretary and treasurer from March 2016 to March 2019. Prior to joining Curis, Mr. Dentzer served as Chief Financial Officer of Dicerna Pharmaceuticals, Inc., a formerly publicly traded biotechnology company, from December 2013 to December 2015. Prior to that, he was the Chief Financial Officer of Valeritas, Inc., a formerly publicly traded medical technology company, from March 2010 to December 2013. Prior to joining Valeritas, Inc., he was the Chief Financial Officer of Amicus Therapeutics, Inc. (Nasdaq: FOLD), a biotechnology company, from October 2006 to October 2009. In prior positions, he spent six years as Corporate Controller of Biogen Inc. (Nasdaq: BIIB), a biotechnology company, and six years in various senior financial roles at E.I. du Pont de Nemours and Company, a chemical, petroleum, and biotechnology company, in the U.S. and Asia. Mr. Dentzer holds a B.A. degree in Philosophy from Boston College and an M.B.A. from the University of Chicago.- James E. Dentzer，他于2013年12月担任财务总监。自2010年3月至2013年12月，他在Valeritas公司担任财务总监，带领其金融团队在C轮筹集了价值1.5亿美元的股票以及价值1亿美元的债务，得到了食品药物管理局（U.S. Food and Drug Administration）的支持和引导，并更大规模的制造并销售V-Go 胰岛素传输设备。在进入Valeritas公司前，即自2006年10月至2009年10月，他在Amicus Therapeutics公司（NASDAQ股票代码FOLD）担任财务总监，引领公司进行了D系列的优先股融资以及首次公开募股。他在Biogen Idec公司担任了6年财务总监，并在E.I. du Pont de Nemours 公司及其位于美国和亚洲的分公司里担任了6年的各种高级财务管理职位。他在波士顿学院（Boston College）获得哲学学士学位，并在芝加哥大学（University of Chicago）获得工商管理硕士学位。
- James E. Dentzer was appointed to Imunon, Inc. Board of Directors in September 2022. He has been President and Chief Executive Officer and a member of the Board of Directors of Curis, Inc. (Nasdaq: CRIS) since September 2018. From March 2018 to September 2018, Mr. Dentzer served as Curis' Chief Operating Officer and Chief Financial Officer. From March 2016 to March 2018, Mr. Dentzer served as Curis' Chief Administrative Officer and Chief Financial Officer. Mr. Dentzer has also held the positions of secretary and treasurer from March 2016 to March 2019. Prior to joining Curis, Mr. Dentzer served as Chief Financial Officer of Dicerna Pharmaceuticals, Inc., a formerly publicly traded biotechnology company, from December 2013 to December 2015. Prior to that, he was the Chief Financial Officer of Valeritas, Inc., a formerly publicly traded medical technology company, from March 2010 to December 2013. Prior to joining Valeritas, Inc., he was the Chief Financial Officer of Amicus Therapeutics, Inc. (Nasdaq: FOLD), a biotechnology company, from October 2006 to October 2009. In prior positions, he spent six years as Corporate Controller of Biogen Inc. (Nasdaq: BIIB), a biotechnology company, and six years in various senior financial roles at E.I. du Pont de Nemours and Company, a chemical, petroleum, and biotechnology company, in the U.S. and Asia. Mr. Dentzer holds a B.A. degree in Philosophy from Boston College and an M.B.A. from the University of Chicago.